Tag

Teva

All articles tagged with #teva

legal-and-antitrust1 year ago•6 min saved

Navigating Antitrust Challenges in Life Sciences Private Equity

Calls for removal of allegedly improperly listed patents in the Orange Book continue, with FTC and Congressional pressure leading some pharmaceutical companies to voluntarily delist challenged patents. Teva faces allegations of delaying generic competition for Copaxone and is involved in a legal dispute with Amneal and Cipla. Additionally, a court grants summary judgment in favor of Align Technology in an antitrust suit related to Invisalign, while another court declines to dismiss monopoly claims against HCA Healthcare and Mission Health Systems. The New York Supreme Court dismisses an antitrust complaint filed by the state accusing CVS of illegal tying in the market for 340B drug rebates.

via WilmerHale|

#antitrust #court-cases #ftc

pharmaceuticals2 years ago•0 min saved

Sanofi and Teva's Collaboration Ignites Competition in IBD Drug Market

Sanofi has secured a deal worth up to $1.5 billion with Teva for the development and launch of Teva's anti-TL1A antibody. Teva will receive an upfront payment of $500 million and up to $1 billion in development and launch milestones. This deal adds fuel to the competition against Merck and Roivant, who are also developing anti-TL1A treatments.

via Endpoints News|

#anti-tl1a #merck #pharmaceuticals

pharmaceuticals2 years ago•7 min saved

SCOTUS decision on 'skinny' label generic drugs sparks concerns for future carve outs.

The US Supreme Court has declined to take up a case involving "skinny" label generic drugs, which could have implications for the generic drug industry. The industry has been able to bring generic drugs to market by carving out the label to avoid certain indications that are still under patent protection. The case in question involved a court battle between Teva and GlaxoSmithKline over GSK’s beta-blocker Coreg (carvedilol), which Teva launched a generic of in 2007.

via Endpoints News|

#generic-drugs #glaxosmithkline #patent-protection